Potassium voltage-gated channel subfamily Q members 2-5 (KCNQ2-5) (KCNQ2-5)

KCNQ2-5 ion channels, also known as neuronal Kv7 channels, are a family of voltage-gated potassium channels essential for regulating electrical activity in the nervous system. These channels are the molecular basis of the M-current, a slowly activating potassium current that acts as a fundamental "brake" on neuronal excitability by stabilizing the membrane potential near the threshold for action potential firing. Primarily localized at critical neuronal sites like the axon initial segment and nodes of Ranvier, they prevent aberrant repetitive firing and maintain rhythmic stability. Genetic mutations in KCNQ2 and KCNQ3 are well-documented causes of neonatal-onset epilepsy and severe developmental and epileptic encephalopathies, while KCNQ4 mutations are linked to progressive hearing loss. Consequently, these channels have emerged as validated therapeutic targets for anti-seizure medications and analgesics. Pharmacological activators, such as the now-withdrawn retigabine and several next-generation compounds in development, work by shifting the channel's activation voltage to more negative levels, thereby suppressing hyperexcitability. Modern drug discovery efforts focus on subtype-selective modulators to mitigate side effects like urinary retention and long-term tissue discoloration while effectively treating epilepsy, neuropathic pain, and potentially neuropsychiatric disorders.

Other names

Neuronal Kv7 channelsKv7.2-7.5 channelsM-channelsPotassium voltage-gated channel subfamily KQT members 2-5KQT-like 2-5

Positive allosteric modulation of voltage-gated potassium channels leading to channel opening and hyperpolarizing shift of the activation curve, which reduces neuronal hyperexcitability.